CYP26C1
CYP26C1 is a member of the cytochrome P450 superfamily of enzymes. These enzymes are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. The CYP26C1 gene is located on chromosome 10 in humans.
Function[edit | edit source]
CYP26C1 is primarily involved in the metabolism of retinoic acid, a derivative of vitamin A that plays a crucial role in cell growth, differentiation, and embryonic development. The enzyme helps to regulate the levels of retinoic acid by converting it into hydroxylated forms, which are then further metabolized and excreted from the body. This regulation is essential for maintaining proper cellular function and preventing the toxic effects of excess retinoic acid.
Gene Structure[edit | edit source]
The CYP26C1 gene consists of several exons and introns, which are transcribed and spliced to produce the mature mRNA. The gene is expressed in various tissues, including the liver, kidney, and brain, indicating its widespread role in retinoic acid metabolism.
Clinical Significance[edit | edit source]
Mutations or alterations in the CYP26C1 gene can lead to abnormal retinoic acid levels, which may result in developmental disorders and diseases. For example, improper regulation of retinoic acid has been linked to conditions such as congenital diaphragmatic hernia and caudal regression syndrome. Research is ongoing to better understand the role of CYP26C1 in these and other conditions.
Related Enzymes[edit | edit source]
CYP26C1 is part of a subfamily of enzymes that includes CYP26A1 and CYP26B1. These enzymes share similar functions in retinoic acid metabolism but may have different tissue distributions and substrate specificities.
Research and Future Directions[edit | edit source]
Ongoing research aims to elucidate the detailed mechanisms by which CYP26C1 regulates retinoic acid levels and to explore its potential as a therapeutic target. Understanding the enzyme's structure and function could lead to the development of drugs that modulate its activity, offering new treatments for diseases related to retinoic acid imbalance.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD